Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations

Nature Medicine
M HowardDavid M Bedwell

Abstract

Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). A single recessive mutation, the deletion of phenylalanine 508 (deltaF508), causes severe CF and resides on 70% of mutant chromosomes. Severe CF is also caused by premature stop mutations, which are found on 5% of CF chromosomes. Here we report that two common, disease-associated stop mutations can be suppressed by treating cells with low doses of the aminoglycoside antibiotic G-418. Aminoglycoside treatment resulted in the expression of full-length CFTR and restored its cyclic AMP-activated chloride channel activity. Another aminoglycoside, gentamicin, also promoted the expression of full-length CFTR. These results suggest that treatment with aminoglycosides may provide a means of restoring CFTR function in patients with this class of mutation.

References

Mar 20, 1991·Journal of Molecular Biology·J M SkuzeskiJ F Atkins
Jan 1, 1990·Critical Reviews in Biochemistry and Molecular Biology·D L HatfieldS Oroszlan
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·B S KeremJ M Rommens
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·T R FuerstB Moss
Feb 1, 1993·Journal of Bioenergetics and Biomembranes·G R Cutting
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·K K McCaughanW P Tate

❮ Previous
Next ❯

Citations

Aug 10, 1999·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·K CzaplinskiS W Peltz
Apr 22, 2008·Molecular Diagnosis & Therapy·Anthony Scimè, Michael A Rudnicki
Nov 26, 2010·Cellular and Molecular Life Sciences : CMLS·Eduardo A DonadiPhilippe Moreau
Mar 17, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ming DuDavid M Bedwell
Jul 23, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Steven M RoweDavid M Bedwell
Sep 5, 2006·Human Genetics·Virginia B MattisChristian L Lorson
Nov 8, 2003·Journal of the Association for Research in Otolaryngology : JARO·P S SteygerC F Dai
Apr 3, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stéphane AuvinAndrey Mazarati
Jul 23, 1998·The American Journal of Medicine·E M SchwiebertC M Fuller
Mar 31, 2000·Pharmacology & Therapeutics·A K LarsenA Skladanowski
Sep 9, 1999·Journal of Reproductive Immunology·A Arnaiz-VillenaJ Martinez-Laso
Oct 26, 2002·Journal of Hepatology·M Fatima Leite, Michael H Nathanson
Feb 14, 1998·Neurobiology of Aging·G E GibsonR F Cowburn
Mar 26, 2003·Drug Discovery Today·Guido J R ZamanConstant A A van Boeckel
Aug 26, 1999·Drug Discovery Today·D J Ecker, R H Griffey
Dec 5, 2000·Current Opinion in Chemical Biology·S J Sucheck, C H Wong
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Anne VankeerberghenJean-Jacques Cassiman
Jun 19, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Liutao DuRichard A Gatti
Sep 7, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Martin F Lavin
Feb 13, 2008·Nature Clinical Practice. Neurology·Leland E Lim, Thomas A Rando
Apr 1, 1996·Nature Medicine·S J Delaney, B J Wainwright
Jun 1, 1996·Nature Medicine·H C Dietz, A Hamosh
Nov 14, 1997·Nature Medicine·D M BedwellE J Sorscher
Aug 8, 2008·Chemical Communications : Chem Comm·Nicholas M Llewellyn, Jonathan B Spencer
Nov 13, 2001·Clinical and Experimental Pharmacology & Physiology·K Kunzelmann, M Mall
Aug 28, 2003·Annals of Human Genetics·Rebecca K Rowntree, Ann Harris
Mar 18, 2000·Kidney International·P L Zeitlin
Jan 12, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Akos ZsemberyJürg Graf
May 29, 1997·The New England Journal of Medicine·M J Ackerman, D E Clapham
Oct 10, 2003·The New England Journal of Medicine·Michael WilschanskiEitan Kerem
Sep 8, 2010·The New England Journal of Medicine·Harry C Dietz
Feb 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ming DuDavid M Bedwell
Feb 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Douglas S AuldJames Inglese
Dec 16, 2005·The Journal of Biological Chemistry·Diane E HandyJoseph Loscalzo
Sep 23, 2009·The Journal of Experimental Medicine·Liutao DuRichard A Gatti
Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy R Pasquale, James S Tan
May 1, 1999·Human Gene Therapy·M K MansouraA S Verkman
Jan 23, 2004·Nucleic Acids Research·Sanaa TorkCéline Fabret
May 27, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Roser TorraAlberto Ortiz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.